Oncogenic pathway identification

Groundbreaking molecular phenotyping

Revealing tumor-driving mechanisms

OncoSignal assesses the activity of cell signal transduction pathways which drive tumor growth.

mRNA levels regulated by the pathway transcription factor are measured and translated into a quantitative pathway activity score.

OncoSignal pathway analysis can be used to reveal aberrant activity of signaling pathways in tumor cells enabling applications for drug response monitoring*, stratification for clinical trials and for cancer research.

*For Research Use Only – not for use in diagnostic procedures.

OncoSignal pathway analysis

Signaling pathway activity

*For Research Use Only – not for use in diagnostic procedures.

How does it work?

Please view the OncoSignal video to discover the unique features of our solution.

Products & Services

OncoSignal service testing

Full service: tissue/RNA-in, result-out
ISO13485 compliant
ER, AR, PI3K, MAPK, Hedgehog, TGFβ, Notch pathways
RNA quality check on each sample
Compatible for FFPE, FF and extracted RNA samples

OncoSignal analysis kit

qPCR-based method allowing in-house testing using standard lab equipment
Access to Philips software portal for data analysis and generation of the pathway activity report
ER, AR, PI3K, MAPK pathways
Compatible for FFPE samples

OncoSignal data analysis

Analysis of microarray and RNA-Seq data (generated according to specific requirements)
ER, AR, PI3K, MAPK, Hedgehog, TGFβ, Notch, Wnt pathways
Data quality checks included

OncoSignal is available for Research Use Only – not for use in diagnostic procedures.

Pathway Activity Report

The quantitative pathway activity scores on a 0 to 100 scale (CI = 95%) are presented in the OncoSignal pathway activity report for the pathways requested.

Applications

OncoSignal pathway activity analysis can be used for:

Molecular phenotypic characterization
Model selection for optimal study design
Determination of drug-pathway interaction
Predicting and monitoring drug response*
Patient stratification for clinical trials

Tests are conducted using RNA extracted from fresh frozen (FF) or formalin-fixed paraffin embedded (FFPE) tissue samples, cell cultures or PDX models. For examples on the use of OncoSignal, please request the OncoSignal application note via oncosignal@philips.com.

*For Research Use Only – not for use in diagnostic procedures.

Upcoming events

OncoSignal at events 2019

AACR-NCI-EORTC in Boston, USA	October 26-30 Booth #1507
AMP in Baltimore, USA	November 7-9 Booth #2537
SABCS in San Antonio, USA	December 10-14 Booth #806

OncoSignal at events 2020

EBCSS in Edinburgh, Scotland	February 29 Booth #tbd
T-ALL in Utrecht, Netherlands	March 20-22 Booth #tbd
AACR in San Diego, USA	April 24-29 Booth #1717
EACR in Turin, Italy	June 17-20 Booth #D7

Recent publications

Androgen receptor pathway activity and the ratio between androgen and estrogen receptor pathway activity in breast cancer subtypes, Poster, SABCS 2019
The MAPK pathway is variably active across breast cancer subtypes, and increased activity may be associated with hormonal therapy resistance, Poster, SABCS 2019
Signal transduction pathway activity in normal fallopian tube epithelium and high-grade serous carcinoma, Poster, ESGO 2019
Measuring functional PI3K and NFkB pathway activity to distinguish between short-term and long-term disease-free survivors of high grade serous ovarian cancer, Poster, ESGO 2019
Quantitative measurements of functional activity of the TGF&[beta] and MAPK-AP1 pathways in colon cancer provides information on their role in cancer development and metastasis, Poster, ANE 2019

Fulvestrant resistance in an MCF-7 model for breast cancer is associated with complete loss of ER pathway activity and gain of MAPK-AP1 pathway activity, Poster, ANE 2019
Measurement of decrease in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival in ER positive breast cancer patients, Poster, ESMO 2019

• Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer; Cancers, 2019

• Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types’; Nature Scientific Reports, 2019

• Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model; The American Journal of Pathology, 2018

For copies of one of the above mentioned publications, please email us at oncosignal@philips.com.

Publications

For copies of one of the above and below mentioned publications, please email us at oncosignal@philips.com.

Heterogeneity in Signaling Pathway Activity within Primary Breast Cancer and between Primary and Metastases, Poster, ASCO 2019
ER pathway activity score as a predictive biomarker to improve stratification for neo-adjuvant endocrine therapy, Poster, ESMO Breast Congress 2019
Quantitative measurement of multiple signal transduction pathway activities in cell and tissue culture, including cancer, fibroblasts, and immune cell types: a new way forward to standardization of cell culture experiments, Poster, AACR 2019
Breast cancer induces a tolerogenic state of healthy activated CD4+ T-cells, characterized by reduced PI3K, NFκB, JAK-STAT, Notch, and increased TGFβ pathway activity, Poster, AACR 2019
Elucidating the role of functional signal trasnduction pathway activity in sensitivity and response of triple negative breast cancer PDxs to PI3K inhibition, Poster, SABCS 2018
Does Hormone Expression by IHC predict ER Pathway Activity? An Analysis in A Metastatic Breast Cancer Patient Cohort. Poster, SABCS 2018
Assays for measurement of functional signal transduction pathway activity in any cell or tissue sample, Poster, Keystone 2018
Signal transduction pathway activity before and after neoadjuvant treatment in esophageal cancer, Poster, ESMO 2018
Estrogen receptor pathway activity in endometrial carcinomas and its relation to tumor grade and disease related mortality, Poster, ESMO 2018
Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma, Poster, ESMO 2018
Assessment of functional signal transduction pathway activity in patient-derived tumor xenografts to predict and evaluate therapy response, Poster, ENA 2018
Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma, Poster, EACR 2018
Robust measurement of signal transduction pathway activity in cancer using RNA sequencing on cells and FFPE tissue, Poster, AMPEu 2018
Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors, Poster, AACR 2018
Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types, Poster, AACR 2018
Measuring functional PI3K pathway activity in cancer tissue using FOXO target gene expression in a knowledge-based computational model, Poster, SABCS 2017
Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell, Nature Scientific Reports, 2017
Assessing functional androgen receptor (AR) pathway activity using a computational model, Poster, ESMO 2017
Oncogenic signal transduction pathway activity in glioblastoma and relation to therapy response, Poster, EACR Cancer Genomics 2017
Analysis of active oncogenic signal transduction pathways in HGS ovarian cancer HH pathway activity associated with platin resistance, Poster, AMP 2017
Elucidating pediatric brain tumor pathophysiology by assessing signal transduction pathway activation, Poster, AACR 2017
Predicting first line tamoxifen response of recurrent ER+ breast cancer patients based on transcriptional activity of signaling pathways, Poster, AACR 2016
Prognosis within different breast cancer subtypes using functional activity of signaling pathways, Poster, AACR 2015
Assessing functional ER pathway activity using a computational pathway model, Poster, EACR 2014
Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways, Cancer Research, 2014
Knowledge-based computational models, Oncotarget, 2014
Identifying tumor driving signaling pathways using computational pathway models, Poster, AACR 2013
Personalized Cancer Treatment Selection using Computational Signaling Pathway Models, Poster, SABCS 2011

Clinical Advisory Board

Fabrice André, MD, PhD, Gustave Roussy, Villejuif (France)
Carlos L. Arteaga, MD, UT Southwestern Medical Center, Dallas (USA)
Jean-Yves Blay, MD, PhD, Centre Léon Bérard, Lyon (France)
Fabien Calvo, MD, PhD, University of Paris Denis Diderot Medical School, Paris (France)
Carla van Herpen, MD, PhD, Radboud University Medical Center, Nijmegen (The Netherlands)
Hatim Husain, MD, University of California, San Diego (USA)
Cynthia Ma, MD, PhD, Washington University Medical School, St. Louis (USA)
Christophe Massard, MD, PhD, Gustave Roussy, Villejuif (France)
Hans Prenen, MD, PhD, Antwerp University Hospital, Edegem (Belgium)
Dirk de Ruysscher, MD, PhD, Maastro, Maastricht University Medical Center, Maastricht (The Netherlands)
Cristina Saura, MD, PhD, Vall d'Hebron University Hospital, Barcelona (Spain)
Karen Willard-Gallo, PhD, Institut Jules Bordet, Brussels (Belgium)

EIT Health

Functional signaling Pathway ACtivity complementing DNA Mutation ANalysis for precision medicine (PACMAN)

PACMAN will test how well the OncoSignal solution increases the effectiveness of new, personalised cancer therapy. Significant progress has been made with targeted drugs that block tumour-driving molecular pathways, but it is still difficult to predict how patients will respond. OncoSignal was designed to improve selection of optimal personalised therapy for individual patients.

Impact

OncoSignal will contribute to disruption of cancer care by moving from treatment based on cancer type to tumour biology. Assessment of the functional molecular phenotype will provide improved therapy response prediction compared to DNA genotyping analysis alone. The project promises to:

improve clinical outcomes, especially for hard-to-treat cancers;
reduce unnecessary side effects from ineffective therapies;
save costs due to more effective (personalised) therapies.

For more information, please visit www.eithealth.eu/pacman.

Contact information

* This field is mandatory

Country

First name*

First name (phonetic)

Last name*

Last name (phonetic)

Salutation

Academic title

Email address*

Business phone

Company*

Job title

Industry

Function

Specialty

Department

State or Province

City

Address

Zip or Postal Code

By specifying your reason for contact we will be able to provide you with a better service.

Follow up information

Preferred method of contact

Best time to call

Estimated time of purchase

Comments

What is cross border data transfer?

I agree on cross-border transfer of personal information.

I would like to receive marketing related electronic communications about Philips products, services, events and promotions that may be relevant to me based on my user preferences and behaviour.